4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole → HCID 44543766, compound

HRID 2093408Notes

Reaction equation

HRID 2093408 reaction equation
Cl[C:2]1[N:10]=[C:9]2[C:5]([N:6]=[CH:7][N:8]2[CH3:11])=[C:4]([N:12]2[CH2:17][CH2:16][O:15][CH2:14][CH2:13]2)[N:3]=1.CC1(C)C(C)(C)OB([C:26]2[CH:34]=[CH:33][CH:32]=[C:31]3[C:27]=2[CH:28]=[N:29][NH:30]3)O1>>[NH:30]1[C:31]2[C:27](=[C:26]([C:2]3[N:10]=[C:9]4[C:5]([N:6]=[CH:7][N:8]4[CH3:11])=[C:4]([N:12]4[CH2:17][CH2:16][O:15][CH2:14][CH2:13]4)[N:3]=3)[CH:34]=[CH:33][CH:32]=2)[CH:28]=[N:29]1

Participants

3

Reactant 2

HCID 454801864-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazoleHCID 715006872-Chloro-9-methyl-6-(4-morpholinyl)-9H-purine

Product 1

HCID 44543766HCID 44543766, compound

Procedure

4-(2-Chloro-9-methyl-9H-purin-6-yl)morpholine (20 mg) was reacted with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole via General Procedure A and purified via reverse phase HPLC to give 13.8 mg of 129 as a white solid. MS (Q1) 336.2 (M)+

Workup

  1. custompurified via reverse phase HPLC

Sources & evidence

ORD record
ord-b811444487074a4da3853508e185fcc5
Source dataset
uspto-grants-2013_05
Patent number
US08445487B2

Reaction notes

Loading…